N4P vs. CEL, HELD, HLN, BXP, HIK, HCM, INDV, AMYT, APH, and AGY
Should you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Celadon Pharmaceuticals (CEL), Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), and Allergy Therapeutics (AGY). These companies are all part of the "drug manufacturers - specialty & generic" industry.
N4 Pharma vs.
Celadon Pharmaceuticals (LON:CEL) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
N4 Pharma has lower revenue, but higher earnings than Celadon Pharmaceuticals. N4 Pharma is trading at a lower price-to-earnings ratio than Celadon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by insiders. Comparatively, 18.0% of N4 Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
N4 Pharma received 99 more outperform votes than Celadon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Celadon Pharmaceuticals an outperform vote while only 65.61% of users gave N4 Pharma an outperform vote.
Celadon Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500.
In the previous week, Celadon Pharmaceuticals had 1 more articles in the media than N4 Pharma. MarketBeat recorded 1 mentions for Celadon Pharmaceuticals and 0 mentions for N4 Pharma. Celadon Pharmaceuticals' average media sentiment score of 0.20 beat N4 Pharma's score of 0.00 indicating that Celadon Pharmaceuticals is being referred to more favorably in the media.
Celadon Pharmaceuticals has a net margin of -4,024.62% compared to N4 Pharma's net margin of -18,399.86%. N4 Pharma's return on equity of -90.68% beat Celadon Pharmaceuticals' return on equity.
Summary
Celadon Pharmaceuticals beats N4 Pharma on 10 of the 15 factors compared between the two stocks.
Get N4 Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
N4 Pharma Competitors List
Related Companies and Tools
This page (LON:N4P) was last updated on 5/1/2025 by MarketBeat.com Staff
